X0609 4 2026-08-26 0001677077 Alzamend Neuro, Inc. ALZN 0001212502 AULT MILTON C III false 11411 SOUTHERN HIGHLANDS PARKWAY SUITE 190 LAS VEGAS NV 89141 true false false false 0 Common Stock 2026-08-26 4 S false 2000 1.5581 D 0 D Common Stock 116648 I By Ault Lending, LLC Common Stock 11068 I By Ault Life Sciences, Inc. Common Stock 61 I By Ault Life Sciences Fund, LLC The sale of these shares is a matchable transaction subject to Section 16(b) of the Securities Exchange Act of 1934. The reporting person has calculated a short-swing profit in connection with such matchable transactions, which the reporting person intends to disgorge to the Issuer. The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sale price of $1.5581. The range of sale prices on the transaction date was $1.55 to $1.5619 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. Ault Lending, LLC ("Ault Lending"), is a wholly-owned subsidiary of Ault Capital Group, Inc. ("ACG"). ACG is a wholly-owned subsidiary of Hyperscale Data, Inc. ("HSD"). Mr. Ault, the Executive Chairman of HSD, is deemed to have voting and investment power with respect to the securities held of record by Ault Lending. Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences, Inc. Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences Fund, LLC. Mr. Ault, the Executive Chairman of HSD, which wholly owns ACG, which in turn wholly owns Ault Lending, is a director of the Issuer. For purposes of Section 16 of the Exchange Act, each of HSD, ACG and Ault Lending may be deemed a director by deputization by virtue of their respective representation on the Board of Directors of the Issuer. /s/ Milton C. Ault, III 2026-08-31